37 related articles for article (PubMed ID: 29561300)
1. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
Wang H; Xu T; Zheng L; Li G
Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301
[TBL] [Abstract][Full Text] [Related]
2. The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
Marchetti C; Fagotti A; Tombolini V; Scambia G; De Felice F
Ann Surg Oncol; 2021 Jun; 28(6):3258-3263. PubMed ID: 33067742
[TBL] [Abstract][Full Text] [Related]
3. Surgery
Capozzi VA; Rosati A; Turco LC; Sozzi G; Riccò M; Chiofalo B; Vizzielli G
Gland Surg; 2020 Aug; 9(4):1112-1117. PubMed ID: 32953626
[TBL] [Abstract][Full Text] [Related]
4. Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
Conte C; Fagotti A; Avesani G; Trombadori C; Federico A; D'Indinosante M; Giudice MT; Pelligra S; Lodoli C; Marchetti C; Ferrandina G; Scambia G; Gallotta V
Ann Transl Med; 2021 Mar; 9(6):510. PubMed ID: 33850907
[TBL] [Abstract][Full Text] [Related]
5. Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Marchetti C; Rosati A; Scaletta G; Pietragalla A; Arcieri M; Ergasti R; Palluzzi E; Scambia G; Fagotti A
Gynecol Oncol; 2019 Dec; 155(3):400-405. PubMed ID: 31606285
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer.
Zou R; Jiang Q; Luo X; Chen M; Yuan L; Yao L
World J Surg Oncol; 2023 Nov; 21(1):375. PubMed ID: 38037085
[TBL] [Abstract][Full Text] [Related]
7. The current role of secondary cytoreductive surgery for recurrent ovarian cancer.
de Bree E; Michelakis D; Anagnostopoulou E
Front Oncol; 2022; 12():1029976. PubMed ID: 36338689
[TBL] [Abstract][Full Text] [Related]
8. Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer.
Jiang C; Li Z
Front Oncol; 2021; 11():674637. PubMed ID: 34631517
[TBL] [Abstract][Full Text] [Related]
9. Secondary debulking for ovarian carcinoma relapse: The R-R dilemma – is the prognosis different for residual or recurrent disease?
Spiliotis JD; Iavazzo C; Kopanakis ND; Christopoulou A
J Turk Ger Gynecol Assoc; 2019 Nov; 20(4):213-217. PubMed ID: 31362486
[TBL] [Abstract][Full Text] [Related]
10. When should Surgery be used for Recurrent Ovarian Carcinoma?
Bommert M; Harter P; Heitz F; du Bois A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):493-497. PubMed ID: 29743148
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for secondary debulking in ovarian cancer? A review of the current literature.
Krause D; Richardson DL
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):1-5. PubMed ID: 36239548
[TBL] [Abstract][Full Text] [Related]
12. Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery.
Laga T; Lambrechts S; Laenen A; Van Nieuwenhuysen E; Han SN; Vergote I
Int J Gynecol Cancer; 2018 May; 28(4):721-728. PubMed ID: 29561300
[TBL] [Abstract][Full Text] [Related]
13. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
14. [Recurrent ovarian cancer--qualification and results of surgical treatment].
Derlatkal P; Grabowska-Derlatka L; Jalinik K; Danska-Bidzińska A
Ginekol Pol; 2015 Dec; 86(12):902-6. PubMed ID: 26995939
[TBL] [Abstract][Full Text] [Related]
15. Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system.
Laas E; Luyckx M; De Cuypere M; Selle F; Daraï E; Querleu D; Rouzier R; Chéreau E
Int J Gynecol Cancer; 2014 Feb; 24(2):238-46. PubMed ID: 24457552
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
